inPractice® - Integrase Inhibitors, Maraviroc, and Dyslipidemia

Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
Last Reviewed: 10/10/18 (What's New)

Summary

Clinical trial data suggest raltegravir, elvitegravir, dolutegravir, bictegravir, and maraviroc have little effect on lipid levels^{[Sierra-Madero 2010; Rockstroh 2013; Sax 2012; DeJesus 2012; Cooper 2010; Raffi 2013; Walmsley 2013; Molina 2015; Gallant 2017; Sax 2017; Daar 2017]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Dyslipidemia, Treatment Complications